Literature DB >> 33882195

Multivalent Aptamer-Functionalized Single-Strand RNA Origami as Effective, Target-Specific Anticoagulants with Corresponding Reversal Agents.

Abhichart Krissanaprasit1, Carson M Key1, Kristen Froehlich2, Sahil Pontula3, Emily Mihalko2, Daniel M Dupont4, Ebbe S Andersen4, Jørgen Kjems4, Ashley C Brown2,5, Thomas H LaBean1,5.   

Abstract

Anticoagulants are commonly utilized during surgeries and to treat thrombotic diseases like stroke and deep vein thrombosis. However, conventional anticoagulants have serious side-effects, narrow therapeutic windows, and lack safe reversal agents (antidotes). Here, an alternative RNA origami displaying RNA aptamers as target-specific anticoagulant is described. Improved design and construction techniques for self-folding, single-molecule RNA origami as a platform for displaying pre-selected RNA aptamers with precise orientational and spatial control are reported. Nuclease resistance is added using 2'-fluoro-modified pyrimidines during in vitro transcription. When four aptamers are displayed on the RNA origami platform, the measured thrombin inhibition and anticoagulation activity is higher than observed for free aptamers, ssRNA-linked RNA aptamers, and RNA origami displaying fewer aptamers. Importantly, thrombin inhibition is immediately switched off by addition of specific reversal agents. Results for single-stranded DNA (ssDNA) and single-stranded peptide nucleic acid (PNA) antidotes show restoration of 63% and 95% coagulation activity, respectively. To demonstrate potential for practical, long-term storage for clinical use, RNA origami is freeze-dried, and stored at room temperature. Freshly produced and freeze-dried RNA show identical levels of activity in coagulation assays. Compared to current commercial intravenous anticoagulants, RNA origami-based molecules show promise as safer alternatives with rapid activity switching for future therapeutic applications.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  RNA nanotechnology; RNA origami; anticoagulants; aptamers; direct thrombin inhibitors; nucleic acids; reversal agents

Year:  2021        PMID: 33882195     DOI: 10.1002/adhm.202001826

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  5 in total

1.  The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field.

Authors:  Morgan Chandler; Brittany Johnson; Emil Khisamutdinov; Marina A Dobrovolskaia; Joanna Sztuba-Solinska; Aliasger K Salem; Koen Breyne; Roger Chammas; Nils G Walter; Lydia M Contreras; Peixuan Guo; Kirill A Afonin
Journal:  ACS Nano       Date:  2021-10-22       Impact factor: 18.027

Review 2.  The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development.

Authors:  Xin Li; Abhjeet S Bhullar; Daniel W Binzel; Peixuan Guo
Journal:  Adv Drug Deliv Rev       Date:  2022-05-05       Impact factor: 17.873

Review 3.  Application of Nucleic Acid Frameworks in the Construction of Nanostructures and Cascade Biocatalysts: Recent Progress and Perspective.

Authors:  Gan Zhu; Ping Song; Jing Wu; Minglan Luo; Zhipeng Chen; Tingjian Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-01-07

4.  Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.

Authors:  Haibin Wu; Liyu Zhang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Ruiping Liu; Huafeng Fan; Yang Chen; Hui Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 5.  Multivalent Aptamer Approach: Designs, Strategies, and Applications.

Authors:  Zhong Wang; Xiuying Yang; Nicholas Zhou Lee; Xudong Cao
Journal:  Micromachines (Basel)       Date:  2022-03-12       Impact factor: 2.891

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.